3 Results Found

Advanced Search

Select all

Results per page

Select all

Feature Paper
Article

28 Citations

7,232 Views

11 Pages

Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke

Garzón Fernando,
Rodríguez Yamila,
García Julio Cesar and
Rama Ramón

Behav. Sci.2018, 8(2), 26;https://doi.org/10.3390/bs8020026

-

13 February 2018

Erythropoietin (EPO) is a glycoprotein initially identified as a hormone synthesized and secreted by the kidney that regulates erythropoiesis. EPO, and a group of its derivatives, are being evaluated as possible neuroprotective agents in cerebral isc...

Full Article

Article

1 Citations

2,185 Views

17 Pages

Subchronic Intranasal Administration of NeuroEPO Reduces Long-Term Consequences of Severe Traumatic Brain Injury in Male Rats

Félix Iván López-Preza,
Maria de los Angeles Nuñez-Lumbreras,
Iliana Sosa-Testé,
Alonso Fernández-Guasti,
Luis Concha,
Teresita Rodríguez-Obaya and
Luisa Rocha

Antioxidants2025, 14(6), 710;https://doi.org/10.3390/antiox14060710

-

11 June 2025

Current treatments fail to prevent long-term consequences induced by a severe traumatic brain injury (TBI). This study aimed to evaluate the efficacy of repetitive intranasal administration of NeuroEPO (a derivative of erythropoietin) on long-term al...

Full Article

Article

17 Citations

5,425 Views

9 Pages

Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease

Ivonne Pedroso,
Marité Garcia,
Enrique Casabona,
Lilia Morales,
Maria Luisa Bringas,
Leslie Pérez,
Teresita Rodríguez,
Ileana Sosa,
Yordanka Ricardo and
Daniel Amaro
+ 1 author

Behav. Sci.2018, 8(5), 51;https://doi.org/10.3390/bs8050051

-

21 May 2018

Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research...

Full Article